ChitogenX Inc. (CHNXF)

0.0354 -0.0146 (-29.15%) As of 10:12AM EDT. Market open.

ChitogenX Inc.

16667 Hymus Boulevard
Kirkland, QC H9H 4R9
Canada
514-261-4735
https://www.chitogenx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pierre Laurin B.Sc.Pharm., M.Sc.	Interim CEO & Independent Chairman	N/A	N/A	1961
Mr. Luc Mainville M.B.A, M.B.A.	Senior VP & CFO	131.01k	N/A	1964
Mr. Guy-Paul Allard	VP of Legal Affairs & Corporate Secretary	N/A	N/A	N/A
Dr. Jonathan Sackier	Senior Vice President of Medical Affairs	165.26k	N/A	N/A
Mr. Frederic Dumais	Director of Communications & Investor Relations	N/A	N/A	N/A
Benedek Simo	Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.

Corporate governance

ChitogenX Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.